By physician referral or invitation only

A Phase I, Randomized, Standard-Care-Controlled Study of the Safety and Efficacy of Intravenous Delivery of Lung Spheroid Cells in Patients with Idiopathic Pulmonary Fibrosis

Primary: To demonstrate the safety of autologous LSCs administered by intravenous infusion in patients with idiopathic pulmonary fibrosis. Secondary: To demonstrate the efficacy of autologous LSCs administered by intravenous infusion in patients with idiopathic pulmonary fibrosis.

Age & Gender

50 years ~ 80 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study is recruiting by invitation only.

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Leonard Lobo
Medicine-Pulmonary

Study Type

Clinical or Medical
Interventional

Study Topics

Lungs and Breathing
Rare Diseases

IRB Number

18-1430

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.